Yeji daily digest
Tue, May 26, 2026 — Wed, Sep 23, 2026
4 catalysts ahead · 5 insider signals
Insider signals · last 90 days
- $ABSI — Pangalos Menelas N (Director) bought $201K on 2026-05-13.
- $CORT — BAKER G LEONARD JR (Director) bought $2.50M on 2026-03-17.
- $CORT — BAKER G LEONARD JR (Director) bought $813K on 2026-03-17.
- $ABSI — Busch Andreas (Chief Innovation Officer) bought $229K on 2026-03-12.
- $ABSI — Pangalos Menelas N (Director) bought $206K on 2026-02-27.
Upcoming catalysts · next 120 days
### Sat, Jul 11, 2026
- $CORT — relacorilant (hypertension secondary to hypercortisolism) · PDUFA
The FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of July 11, 2026 for relacorilant as a treatment for patients with platinum-resistant ovarian cancer.
### Sun, Aug 23, 2026
- $RARE — pariglasgene brecaparvovec (Glycogen Storage Disease Type Ia (GSDIa)) · PDUFA
The FDA granted the BLA Priority Review and assigned a Prescription Drug User Fee Act (PDUFA) action date of August 23, 2026.
### Sat, Sep 19, 2026
- $RARE — ux111 (Sanfilippo syndrome Type A (MPS IIIA)) · PDUFA
The FDA set a Prescription Drug User Fee Act (PDUFA) action date of September 19, 2026.
### Tue, Sep 22, 2026
- $IONS — zilganersen (Alexander disease (AxD)) · PDUFA
Zilganersen is currently under Priority Review by the U.S. Food and Drug Administration with a Prescription Drug User Fee Act action date of September 22, 2026.
Yeji surfaces biotech catalysts from SEC filings, ClinicalTrials.gov, and the FDA. Not investment advice — see disclaimer.